In recent years the numbers of observational reports in the medical field have exploded. Several reasons might explain such a huge increase in observational clinical research. First, the increasing expectations of people regarding their national health systems associated with their exponential cost and, consequently, the need to know how the declining resources are used. Secondly, understanding the current epidemiology of diseases and therapies to make reasonable estimates of the needs for care and expenditure in the future. Thirdly, to allow physicians and scientists to learn more about the incidence and course of diseases by observing 'clinical practice ' What is 'clinical practice'? Clarifying this is important in order to interpret the observational findings correctly. As elegantly reported by Gabbay et al., 1 the majority of clinicians rarely access and use explicit evidence from research or other sources directly. They instead rely on 'mindlines' generated by a number of sources of varying degrees of reliabitiy, collectively reinforced, resulting in individual 'internalized, tacit, guidelines'. These can be far removed from the official recommendations; however, they guide the physician in his clinical practice. A similar process also of course applies to the patient; mixing information obtained from different sources leads to individual beliefs guiding patient behaviour (i.e. acceptance of treatment and adherence both to prescribed medications and an appropriate lifestyle over time). All this results in so-called 'clinical practice', which is the object of observational medical research. On the therapeutic front, clinical practice lies in both physician prescriptions (adherence to guideline recommendations) and patient adherence to the prescriptions over time. Some of the vast array of possible aims of observational medical research are reported in Table 1 . The current limitations of postmarketing safety analyses of both drugs and devices deserves special consideration. Spontaneous reports contain only those events or reactions submitted voluntarily either to a regulatory authority or to the drug manufacturer by consumers and/or members of the health profession. The information is often incomplete and not verified scientifically or otherwise. Often there is no certainty that the suspected therapeutic agent caused the reported reaction, as physicians are encouraged to report suspected reactions. Accordingly, the reporting rate is subject to biases and various external factors, including an increased reporting during the first 2 years or so of the launch of a new therapeutic tool as compared with the remaining years of use. Specific observational networks with huge support from information technology have been structured or are being implemented in several countries, in particular in the USA, 2 aimed at detecting and confirming signals rapidly and quantitatively. According to the multiplicity of aims of observational research, a number of methodological approaches have been described and discussed. Recently an international initiative of epidemiologists, methodologists, researchers, and journal editors reformulated the principles of a methodological approach to different types of medical observational studies. 3 Detailed recommendations on reporting observational longitudinal research have also been published. 4 Adherence to multiple methodological rules, including systematic and accurate checking of data quality (both central checking and peripheral auditing), consecutiveness of patient enrolment, representativeness of the pre-defined setting of recruitment, to be balanced with the independence of the investigators from the funding sources, may be difficult for observational studies often not supported by adequate resources. However, it is necessary to be rigourous in order to avoid misleading and confounding findings. Precise and clear definition of the variables included in the data set is also essential to interpret the data correctly and to allow comparisons across different populations and settings. Imprecise definitions can lead to apparent inconsistencies of the findings, and changes in definitions adopted by the medical community with time can simulate even radical and abrupt epidemiological modifications. The choice of the variables to be collected, consistent with the observational nature and the aim of the study, may be critical. Frequently, a compromise is necessary between the number of desired variables and the work load needed to collect the requested information; in other words, to guarantee the feasibility of the study. The larger the network of participants and the longer the observation period, the simpler the data set should be. In general, before starting a multicentre registry, a few simple issues should be considered: (i) specifying the hypotheses and the primary questions that the registry is expected to address, and the preparation of a consistent case report form; (ii) defining the analytical plan and the publication policy; (iii) securing the quality data control system and the funding support; and (iv) considering whether a pilot phase is needed.
A study aimed at describing trends in incidence and case fatality among Swedish patients with heart failure (HF) according to age (range 18 -84 years) has now been reported. 5 Data were drawn from hospital discharge, nationwide Swedish registries over a period of 20 years (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) , segmented in 4-5 year periods. The attention was focused on young patients, grouped in two age categories, 18 -44 and 45 -54 years, respectively, with the older group (.54 years) taken for comparison. The main findings were a marked increase in incidence of HF in the young ( 50% among people aged ≤ 44 years), peaking in the mid-1990s, and contrasting with the decrease of HF incidence (after 1992-1996) seen among persons .54 years of age. An increase of cardiomyopathy incidence of more than two-fold was observed among all age groups. Case fatality decreased for all age groups until 2001, after which no further significant decrease was observed in the younger groups. An increase of HF hospitalization in the young population, in particular those with a diagnosis of cardiomyopathy, a high case fatality, and the reduction in its incidence having stopped in the last decade are considered epidemiological trends of concern.
The reported study has a number of strengths, related to the valuable structure of the Swedish registries. First, the longitudinal longterm nature of these registries, started . 20 years ago and accurately maintained over time. Secondly, the governmental support with incentives offered to those hospitals which are compliant in feeding the databases, and the essential cooperation given by continuous notifications on the vital status of the patients included in the registries. Thirdly, the consequent real representativeness of the Swedish population by the nationwide registries. Fourthly, the familiarity of the health operators with management of the registry, incorporated into the daily routine, which minimizes missing data and mistakes. Fifthly, the 'all-comers' nature of the registries which allows the investigation of relatively small subgroups without losing representativeness of the relevant population in spite of the relatively low numbers. Finally, the data sets adhere to the 'clinical practice' concept, trying to capture what is considered really important to the public's health. Overall, these characteristics represent an enviable platform of methodological solidity, making these registries an example for all European countries and further afield.
A few limitations of the reported analysis, in part acknowledged by the authors, should be considered. First, as mentioned above, the universal nature of the registry (all hospitals, all patients) results in simple data sets. This requires the difficult exclusion of important variables. For instance, most biological variables are not included in the reported registry; one above all, the left ventricular ejection fraction. In a time of intense research focused on HF with reduced vs. preserved ejection fraction, this lack may be felt as a serious limitation. Secondly, the main findings of the study rest on hospitalization for or with HF (first-ever HF diagnosis code in any position at discharge, not necessarily as the primary diagnosis). It is well known that in the long run changes in national health system structure and rules, availability of facilities, modifications of adopted diagnostic definitions, sensitivity of the physicians toward certain diseases, and so forth, can lead to changes in hospitalization rates for a disease, regardless of its incidence. Thus, taking the HF hospitalization rate as the metric of HF incidence can expose the data risk of non-marginal approximations. This can be managed in part by analytical adjustments, but not all variables can be easily adjusted in the analyses. The authors are aware of this potential limitation of course, but they are confident that the reported changes in hospitalization reflect true epidemiological changes. Thirdly, the gradual increase over time, at any age, of the diagnosis of cardiomyopathy raises further questions. The huge heterogeneity in aetiology and phenotype of cardiomyopathies and the multiplicity of definitions released in the last 20 years by various bodies justifies a robust scepticism of the possibility of measuring true epidemiological changes based on relatively vague definitions of diagnostic discharge codes. For instance, the classification of cardiomyopathy released by the European Society of Cardiology (Working Group on Myocardial and Pericardial Disease) 6 and the American Heart Association 7 in the last few years differ substantially. The issue is not related only to the definition of cardiomyopathy given in the registry, but mostly to the ability of the physicians to interpret uniformly the diagnostic criteria of such a complex disease category. The rate of diagnosis of cardiomyopathy increased in Sweden, but in my view the reported findings do not offer enough evidence that this reflects an epidemiological change.
Conflict of interest: none declared. 
